The first big oncology meeting of the year, AACR, starts next month, and could shed more light on combining checkpoint blockade with modulation of cytokine activity. Investors will also note the unveiling of several competitors in the Kras space, where Mirati and Amgen are the most advanced competitors.
Other key presentations, whose titles have all now been made public, include the first clinical results of Iteos’s anti-Tigit MAb and of Alpine’s ALPN-202. Clinical datasets also feature Iovance’s TILs, due to be filed this year, and an intriguing trial of PD-1 plus Parp inhibition.
2021’s AACR has been split into two virtual meetings, the first of which will likely feature all clinical results, and takes place on April 10-15. Though most abstract titles are out, full texts of clinical trial and late-breaking presentations will remain under wraps until April 9.
New Kras players
In Kras AACR reveals Lilly as a new player with LY3537982, an apparently in-house G12C inhibitor. Still, this is a preclinical abstract, as is that for Boehringer Ingelheim’s low-key G12C challenger BI 1823911.
Clinical Kras watchers will focus on a late-breaker for what promises to be human data on Revolution Medicines’ RMC-4630, an SHP2 inhibitor partnered with Sanofi. The battle to be first to market with a Kras inhibitor remains between Amgen, which has filed sotorasib in the US, and Mirati’s adagrasib.
Meanwhile, some investors will take interest in PD-1/cytokine combos given the recent blow-up of Merck KGaA/Glaxosmithkline’s bintrafusp alfa, an anti-PD-L1/TGF-β trap bispecific. The very same mechanism, albeit with two separately titratable molecules, will be on show at AACR in a clinical presentation from Abbvie’s ABBV-151 with or without budigalimab.
Other cytokine approaches include a first look at clinical data for Kadmon’s KD033, an anti-PD-L1/IL-15 fusion protein. And a Keytruda combo of Sanofi’s SAR444245, a not-alpha IL-2, features in a late-breaker that could inform trials of an in-house Libtayo combination; SAR444245 is in the spotlight after Sanofi bought its originator, Synthorx, for $2.5bn.
Keytruda has an AACR presence in its own right, and two clinical presentations look intriguing. One comprises the first data from the Keylynk-007 basket study, where the Merck & Co drug is being combined with Lynparza; this trial is one of several in the Keylynk programme testing combined blockade of PD-1 and Parp.
Perhaps prostate cancer patients in Keylynk-007 will be of most interest, given standalone activity in this cancer in the Profound and Keynote-199 studies. And separate data on subcutaneous Keytruda, from Keynote-555, will be of interest given Pfizer’s recent push to improve PD-(L)1s’ convenience via sasanlimab.
|Selected AACR 2021 abstracts|
|Keytruda SC||Merck & Co||Keynote-555||SC delivery of anti-PD-1||CT143|
|Keytruda + Lynparza||Merck/Astra||Keylynk-007||PD-1/Parp inhibitor combo||CT178|
|KD033||Kadmon||NCT04242147||Anti-PD-L1/IL-15 fusion protein; first human data||CT227|
|AMG 256||Amgen||NCT04362748||PD-1/IL-21 mutein fusion protein; first human data||CT205|
|ABBV-151 +/- budigalimab||Abbvie/Argenx||NCT03821935||TGFβ trap +/- PD-1 blockade||CT207|
|THOR-707 (SAR444245)||Sanofi (ex Synthorx)||Hammer||Not-alpha IL-2, Keytruda combo||LB041|
|ALPN-202||Alpine||NCT04186637||CD28 co-stimulator/anti-PD-1/anti-CTLA-4; first human data||CT213|
|EOS884448||Iteos||NCT04335253||Anti-Tigit MAb; first human data||CT118|
|SEA-TGT||Seagen||–||Anti-Tigit MAb; preclinical||1583|
|RMC-4630||Revolution Medicines/Sanofi||NCT03634982||SHP2 inhibitor; single-agent study in Ras-driven cancers||LB001|
|LY3537982||Lilly||–||Kras G12C inhibitor; first preclinical data||1259|
|KRAS G12V (ON) inhibitors||Revolution Medicines||–||Kras G12V inhibitor; preclinical discovery data||1260|
|BI 1823911||Boehringer Ingelheim||–||Kras G12C inhibitor; preclinical data||1271|
|Lifileucel||Iovance||C-144-01||Pivotal cohort 2 in melanoma, to support delayed 2021 filing||CT008|
|Oleclumab||Astrazeneca||NCT03381274||Anti-CD73 MAb combo with Tagrisso||CT163|
|INCA00186||Incyte||–||Anti-CD73 MAb; preclinical||LB174|
|Adavosertib||Astrazeneca||ADVL1312||Wee-1 inhibitor; ph2 paediatric trial||CT029|
|ZN-c3||Zentalis||NCT04158336||Wee-1 inhibitor; first human data||CT016|
|AB521||Arcus||–||HIF-2α inhibitor; first preclinical data||1206|
|CMP-001||Checkmate Pharma||NCT02680184||TLR9 agonist (NB Idera failure with tilsotolimod)||CT032|
|ICT01||Imcheck Therapeutics||Eviction||Anti-BTN3A MAb; first-in-human trial||CT034|
|OP-1250||Olema||–||SERD; preclinical data||LB122|
|BLU-263||Blueprint||Unclear||Next-gen Kit inhibitor; first human data||CT122|
|Source: AACR, company communication & clinicaltrials.gov.|
Those keenly tracking first clinical data will also look out for Iteos’s anti-Tigit MAb EOS884448, a cornerstone of the recently Nasdaq-listed Belgian biotech.
Tigit inhibition is becoming competitive, with Roche’s tiragolumab and Merck & Co’s vibostolimab in large pivotal programmes. The former has shown efficacy in NSCLC, albeit in combination with Tecentriq and ironically in PD-L1-high subjects; any efficacy in EOS884448’s monotherapy trial, where patients have no further treatment options, would be positive.
These data are being watched by Arcus, whose own anti-Tigit MAb, domvanalimab, is subject to a possible opt-in by Gilead, but which does not feature at AACR. Another Tigit newcomer, Seagen’s SEA-TGT, has a preclinical AACR poster, while Arcus presents preclinical data on the HIF-2α inhibitor AB521; Merck & Co’s similarly acting, Peleton-derived, belzutifan was recently filed with the FDA.
And investors in Alpine Immune Sciences will look for first clinical data from the Neon-1 trial of ALPN-202, a protein that combines dual checkpoint blockade (PD-L1/CTLA-4) with CD28 co-stimulation. The full impact of this and other clinical presentations will become clearer on April 9.
This year’s AACR conference takes place virtually on April 10-15 and May 17-21. All clinical and late-breaking abstracts appear to have been scheduled for presentation during the first dates.